J 2023

Long-Term Follow-Up of Patients Needing Extracorporeal Membrane Oxygenation Following a Critical Course of COVID-19

GENZOR, Samuel, Pavol POBEHA, Martin SIMEK, Petr JAKUBEC, Jan MIZERA et. al.

Základní údaje

Originální název

Long-Term Follow-Up of Patients Needing Extracorporeal Membrane Oxygenation Following a Critical Course of COVID-19

Autoři

GENZOR, Samuel (203 Česká republika, garant), Pavol POBEHA (705 Slovinsko), Martin SIMEK (203 Česká republika), Petr JAKUBEC (203 Česká republika), Jan MIZERA (203 Česká republika), Martin VYKOPAL (203 Česká republika), Milan SOVA (203 Česká republika, domácí), Jakub VANEK (203 Česká republika) a Jan PRASKO (203 Česká republika)

Vydání

LIFE-BASEL, BASEL, MDPI, 2023, 2075-1729

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 3.200 v roce 2022

Kód RIV

RIV/00216224:14110/23:00131203

Organizační jednotka

Lékařská fakulta

UT WoS

000979236800001

Klíčová slova anglicky

ECMO; COVID-19; long-term outcome

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 11. 7. 2023 10:19, Mgr. Tereza Miškechová

Anotace

V originále

Introduction: Severe respiratory failure is one of the most serious complications of coronavirus disease 2019 (COVID-19). In a small proportion of patients, mechanical ventilation fails to provide adequate oxygenation and extracorporeal membrane oxygenation (ECMO) is needed. The surviving individuals need long-term follow-up as it is not clear what their prognosis is. Aim: To provide a complex clinical picture of patients during follow-up exceeding one year after the ECMO therapy due to severe COVID-19. Methods: All subjects involved in the study required ECMO in the acute stage of COVID-19. The survivors were followed-up for over one year at a specialized respiratory medical center. Results: Of the 41 patients indicated for ECMO, 17 patients (64.7% males) survived. The average age of survivors was 47.8 years, and the average BMI was 34.7 kg center dot m(-2). The duration of ECMO support was 9.4 days. A mild decrease in vital capacity (VC) and transfer factor (DLCO) was observed on the initial follow-up visit (82.1% and 60%, respectively). VC improved by 6.2% and by an additional 7.5% after 6 months and 1 year, respectively. DLCO improved by 21.1% after 6 months and remained stable after 1 year. Post-intensive care consequences included psychological problems and neurological impairment in 29% of patients; 64.7% of the survivors got vaccinated against SARS-CoV-2 within 12 months of hospitalization and 17.6% experienced reinfection with a mild course. Conclusion: The COVID-19 pandemic has significantly increased the need for ECMO. Patients' quality of life after ECMO is temporarily significantly reduced but most patients do not experience permanent disability.